Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) saw an uptick in trading volume on Monday . 601,845 shares were traded during trading, an increase of 205% from the previous session's volume of 197,009 shares.The stock last traded at $23.27 and had previously closed at $23.27.
Chugai Pharmaceutical Stock Up 1.7%
The company has a market cap of $76.85 billion, a PE ratio of 28.83 and a beta of 0.66. The firm's 50-day moving average is $25.56 and its 200-day moving average is $24.39.
Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.19 EPS for the quarter. Chugai Pharmaceutical had a net margin of 33.56% and a return on equity of 21.71%. The firm had revenue of $1.89 billion for the quarter. As a group, equities research analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current fiscal year.
Chugai Pharmaceutical Company Profile
(
Get Free Report)
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
Featured Articles
Before you consider Chugai Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chugai Pharmaceutical wasn't on the list.
While Chugai Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access